Paradigm Biopharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PAR.AX research report →
Price Chart
About the company
Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium, currently undergoing development for the treatment of conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, chikungunya, and acute respiratory distress syndrome. This company commenced operations in 2014.
- CEO
- Paul John Rennie
- IPO
- 2015
- Employees
- 12
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on PAR.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $104.86M
- P/E
- -1.96
- Fwd P/E
- 0.96
- PEG
- 0.02
- P/S
- 1731.19
- P/B
- 12.07
- EV/EBITDA
- -2.24
- Div Yield
- 0.00%
- Gross Margin
- -161.09%
- Op Margin
- -63782.77%
- Net Margin
- -59585.74%
- ROE
- -265.55%
- ROIC
- -492.97%
Latest fiscal year · YoY change
- Revenue
- $52.12K-20.8%
- Gross Profit
- $-19,892-135.0%
- Op Income
- $-22,886,205
- Net Income
- $-18,770,745+68.0%
- EPS
- $-0.06+70.2%
- OCF Growth
- +75.7%
- FCF Growth
- +75.7%
- 52W High
- $0.47
- 52W Low
- $0.14
- 50D MA
- $0.17
- 200D MA
- $0.24
- Beta
- -0.01
- RSI (14)
- 51
- Avg Volume
- 1.91M
No earnings-call transcripts are available for PAR.AX yet.
- Free Float
- 89.6%
- Shares Outstanding
- 599.19M
- Float Shares
- 536.62M
Held by 1 ETFs
Biggest fund positions in PAR.AX by dollar value.
Our PAR.AX coverage
Recent articles, reports, and earnings notes.
No research on PAR.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PAR.AX report →